Katie M Leick1,2,3, Joseph M Obeid1,3, Stefan Bekiranov4, Craig L Slingluff1,3. 1. Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA, USA. 2. Department of Surgery, University of Iowa, Iowa City, IA, USA. 3. Carter Immunology Center, University of Virginia, Charlottesville, VA, USA. 4. Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Abstract
Background: We have identified, in melanomas, a set of genes encoding proteins that mediate mechanical barrier function in normal skin (barrier molecule genes, BMGs) and whose overexpression is associated with decreased immune signatures and shorter patient survival. The most overexpressed of these, filaggrin (FLG), is expressed on chromosome 1q21.3, which also encodes genes of the epidermal differentiation complex (EDC). EDC genes may be regulated by the transcription factors (TFs) AHR and ARNT. We hypothesized that ARNT-related genes would be expressed concordantly with BMG and EDC genes, inversely associated with immune signatures, and enhanced by 1q21.3 copy gain. Methods: Gene expression data from human melanomas in the Cancer Genome Atlas (TCGA), and a validation GEO dataset were evaluated, with copy number profiles from TCGA. Expression of Th1 immune genes and BMG/EDCs at 1q21.3 was visualized using clustered copy number and mRNA profiles. Associations of clusters and 1q21.3 copy number with patient survival and mRNA expression were assessed using Kaplan Meier curves, log-rank tests, and Wilcoxon rank sum tests. Results: BMGs are concordantly expressed with EDC genes. Clustering divided tumors into 4 categories: (1) ImmuneHI, (2) BMG/EDCHI, (3) ARNTHI, (4) Mixed. Both ARNTHI and BMG/EDCHI tumors had low immune signatures and significantly shortened survival. KLF4 and FOXF2 are putative TFs that may regulate these genes. Conclusions: ARNTHI tumors may represent another subset of tumors, in addition to BMG/EDCHI tumors, with barriers to immune infiltrates, likely with different mechanisms. These genes have prognostic significance and may be relevant targets for future therapy.
Background: We have identified, in melanomas, a set of genes encoding proteins that mediate mechanical barrier function in normal skin (barrier molecule genes, BMGs) and whose overexpression is associated with decreased immune signatures and shorter patient survival. The most overexpressed of these, filaggrin (FLG), is expressed on chromosome 1q21.3, which also encodes genes of the epidermal differentiation complex (EDC). EDC genes may be regulated by the transcription factors (TFs) AHR and ARNT. We hypothesized that ARNT-related genes would be expressed concordantly with BMG and EDC genes, inversely associated with immune signatures, and enhanced by 1q21.3 copy gain. Methods: Gene expression data from humanmelanomas in the Cancer Genome Atlas (TCGA), and a validation GEO dataset were evaluated, with copy number profiles from TCGA. Expression of Th1 immune genes and BMG/EDCs at 1q21.3 was visualized using clustered copy number and mRNA profiles. Associations of clusters and 1q21.3 copy number with patient survival and mRNA expression were assessed using Kaplan Meier curves, log-rank tests, and Wilcoxon rank sum tests. Results: BMGs are concordantly expressed with EDC genes. Clustering divided tumors into 4 categories: (1) ImmuneHI, (2) BMG/EDCHI, (3) ARNTHI, (4) Mixed. Both ARNTHI and BMG/EDCHI tumors had low immune signatures and significantly shortened survival. KLF4 and FOXF2 are putative TFs that may regulate these genes. Conclusions: ARNTHI tumors may represent another subset of tumors, in addition to BMG/EDCHI tumors, with barriers to immune infiltrates, likely with different mechanisms. These genes have prognostic significance and may be relevant targets for future therapy.
Authors: Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff Journal: Cancer Res Date: 2012-01-19 Impact factor: 12.701
Authors: Mattias Ormestad; Jeanette Astorga; Henrik Landgren; Tao Wang; Bengt R Johansson; Naoyuki Miura; Peter Carlsson Journal: Development Date: 2006-01-26 Impact factor: 6.868
Authors: Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski Journal: Cancer Res Date: 2009-03-17 Impact factor: 12.701
Authors: Lei Xu; Steven S Shen; Yujin Hoshida; Aravind Subramanian; Ken Ross; Jean-Philippe Brunet; Stephan N Wagner; Sridhar Ramaswamy; Jill P Mesirov; Richard O Hynes Journal: Mol Cancer Res Date: 2008-05 Impact factor: 5.852
Authors: Stuart Macgregor; Grant W Montgomery; Jimmy Z Liu; Zhen Zhen Zhao; Anjali K Henders; Mitchell Stark; Helen Schmid; Elizabeth A Holland; David L Duffy; Mingfeng Zhang; Jodie N Painter; Dale R Nyholt; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Anne E Cust; Mark A Jenkins; David C Whiteman; Håkan Olsson; Susana Puig; Giovanna Bianchi-Scarrà; Johan Hansson; Florence Demenais; Maria Teresa Landi; Tadeusz Dębniak; Rona Mackie; Esther Azizi; Brigitte Bressac-de Paillerets; Alisa M Goldstein; Peter A Kanetsky; Nelleke A Gruis; David E Elder; Julia A Newton-Bishop; D Timothy Bishop; Mark M Iles; Per Helsing; Christopher I Amos; Qingyi Wei; Li-E Wang; Jeffrey E Lee; Abrar A Qureshi; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; Jiali Han; John L Hopper; Jeffrey M Trent; Kevin M Brown; Nicholas G Martin; Graham J Mann; Nicholas K Hayward Journal: Nat Genet Date: 2011-10-09 Impact factor: 38.330